{"transactions":[{"id":697013,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy","published_at":"2026-08-04T20:11:11.000Z","date":"2026-07-31","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date."}],"balance_after":7500,"derivative":{"exercise_price":0.63,"exercise_date":"2027-07-31","expiration_date":"2036-07-31","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-26-085192","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390026085192/ownership.xml","form_type":"4"}},{"id":739468,"issuer":{"id":4928,"kind":"organization","name":"Pacira BioSciences, Inc.","symbol":"PCRX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-13T01:07:30.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":32675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date."}],"balance_after":32675,"derivative":{"exercise_price":23.42,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":32675},"source":{"system":"sec-edgar","filing":"0001628280-26-043007","document":"wk-form4_1781312848.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000162828026043007/wk-form4_1781312848.xml","form_type":"4"}},{"id":1032914,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock Warrant (right to buy)","published_at":"2025-09-24T20:01:57.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"ownership":{"direct":false,"nature":"By Wiggans Living Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":41000,"derivative":{"exercise_price":2.92,"exercise_date":"2026-03-22","expiration_date":"2030-03-22","underlying":"Voting Common Stock","underlying_shares":41000},"source":{"system":"sec-edgar","filing":"0001213900-25-091105","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390025091105/ownership.xml","form_type":"4"}},{"id":1032913,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2025-09-24T20:01:57.000Z","date":"2025-09-22","kind":"purchase","planned":false,"acquired":true,"shares":41000,"price":2.43,"value":99630.0,"ownership":{"direct":false,"nature":"By Wiggans Living Trust"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of voting common stock was purchased together with an accompanying warrant to purchase one share of voting common stock in an underwritten public offering at a combined offering price of $2.43 per share of voting common stock and accompanying warrant."}],"balance_after":41000,"source":{"system":"sec-edgar","filing":"0001213900-25-091105","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390025091105/ownership.xml","form_type":"4"}},{"id":1092067,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-07-03T20:21:18.000Z","date":"2025-07-03","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders."}],"balance_after":7500,"derivative":{"exercise_price":6.77,"exercise_date":"2026-07-03","expiration_date":"2035-07-03","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-25-061493","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390025061493/ownership.xml","form_type":"4"}},{"id":1117635,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-09T20:30:32.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":55000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2025 or (ii) the next Annual Meeting following June 5, 2025, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":55000,"derivative":{"exercise_price":2.55,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":55000},"source":{"system":"sec-edgar","filing":"0001415889-25-016275","document":"form4-06092025_080622.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000141588925016275/form4-06092025_080622.xml","form_type":"4"}},{"id":1484656,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-10T22:20:25.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":7500,"derivative":{"exercise_price":25.41,"exercise_date":"2025-06-06","expiration_date":"2034-06-06","underlying":"Voting Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-051405","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390024051405/ownership.xml","form_type":"4"}},{"id":1486411,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-08T01:45:52.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 5, 2024 or (ii) the next Annual Meeting following June 5, 2024, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":44000,"derivative":{"exercise_price":6.79,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001415889-24-016111","document":"form4-06082024_010649.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000141588924016111/form4-06082024_010649.xml","form_type":"4"}},{"id":1563808,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:54:55.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":14010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0000950170-24-035446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035446/ownership.xml","form_type":"4"}},{"id":1563807,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:54:55.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000950170-24-035446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035446/ownership.xml","form_type":"4"}},{"id":1563806,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:54:55.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":67000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0000950170-24-035446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035446/ownership.xml","form_type":"4"}},{"id":1563805,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (right to buy)","published_at":"2024-03-22T16:54:55.000Z","date":"2024-03-22","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":80000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024, by and among CymaBay Therapeutics, Inc. (\"CymaBay\"), Gilead Sciences, Inc., a Delaware corporation (\"Gilead\"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead (\"Purchaser\"), among other things, Purchaser merged with and into the Company (the \"Merger\").  Accordingly, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes.  Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":4.63,"expiration_date":"2031-04-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0000950170-24-035446","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000095017024035446/ownership.xml","form_type":"4"}},{"id":1669900,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-01-26T18:18:12.000Z","date":"2024-01-24","kind":"grant","planned":false,"acquired":true,"shares":14010,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2024."}],"balance_after":14010,"derivative":{"exercise_price":22.85,"expiration_date":"2034-01-23","underlying":"Common Stock","underlying_shares":14010},"source":{"system":"sec-edgar","filing":"0001062993-24-001420","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299324001420/form4.xml","form_type":"4"}},{"id":1726636,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-30T21:05:16.000Z","date":"2023-11-28","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.6486,"value":6486.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6311 to $0.669, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001213900-23-091458","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023091458/ownership.xml","form_type":"4"}},{"id":1730969,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-22T21:06:03.000Z","date":"2023-11-21","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.6383,"value":6383.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.63 to $0.65, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":40000,"source":{"system":"sec-edgar","filing":"0001213900-23-089579","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023089579/ownership.xml","form_type":"4"}},{"id":1734314,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-21T01:14:16.000Z","date":"2023-11-20","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.6309,"value":6309.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.616 to $0.64, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":30000,"source":{"system":"sec-edgar","filing":"0001213900-23-088896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023088896/ownership.xml","form_type":"4"}},{"id":1734313,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-21T01:14:16.000Z","date":"2023-11-17","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.5966,"value":5966.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5889 to $0.60, inclusive. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer full information regarding the number of shares purchased or sold at each separate price."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001213900-23-088896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023088896/ownership.xml","form_type":"4"}},{"id":1734312,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Voting Common Stock","published_at":"2023-11-21T01:14:16.000Z","date":"2023-11-16","kind":"purchase","planned":false,"acquired":true,"shares":10000,"price":0.5965,"value":5965.0,"ownership":{"direct":true},"balance_after":10000,"source":{"system":"sec-edgar","filing":"0001213900-23-088896","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023088896/ownership.xml","form_type":"4"}},{"id":1751141,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-11-02T22:00:55.000Z","date":"2023-11-01","kind":"grant","planned":false,"acquired":true,"shares":110000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to the option shall vest on November 1, 2024, and 1/48th of the shares subject to the option shall vest following each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on and through each applicable vesting date, inclusive."}],"balance_after":110000,"derivative":{"exercise_price":0.69,"expiration_date":"2033-11-01","underlying":"Voting Common Stock","underlying_shares":110000},"source":{"system":"sec-edgar","filing":"0001213900-23-082883","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000121390023082883/ownership.xml","form_type":"4"}},{"id":1791830,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T18:55:56.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":450000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.98,"expiration_date":"2032-09-13","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-23-047836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919123047836/doc4.xml","form_type":"4"}},{"id":1791829,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T18:55:56.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":985000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each unvested Company Stock Option. Pursuant to the Merger Agreement, each Company Stock Option that was not in the money as of the Effective Time was cancelled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":6.36,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":985000},"source":{"system":"sec-edgar","filing":"0001209191-23-047836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919123047836/doc4.xml","form_type":"4"}},{"id":1791828,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-31T18:55:56.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":562500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"On July 16, 2023, the Issuer's Board of Directors vested in full each option to purchase shares granted under an Issuer equity plan (each, a Company Stock Option) that was outstanding and unvested as of that date. As of the Effective Time, each in-the-money Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled in-the-money Company Stock Option was entitled to receive, in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings and without interest) equal to the product of (x) the total number of shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess of $2.13 over the applicable exercise price per share under such Company Stock Option and (ii) one contingent value right for each share subject thereto."}],"balance_after":0,"derivative":{"exercise_price":2.08,"expiration_date":"2033-01-31","underlying":"Common Stock","underlying_shares":562500},"source":{"system":"sec-edgar","filing":"0001209191-23-047836","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919123047836/doc4.xml","form_type":"4"}},{"id":1791827,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-08-31T18:55:56.000Z","date":"2023-08-31","kind":"other","planned":false,"acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, MediPacific, Inc. (Parent) and MediPacific Sub, Inc., a wholly-owned subsidiary of Parent (Purchaser), dated as of July 16, 2023 (Merger Agreement), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of August 31, 2023 (Effective Time)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of (i) $2.13 in cash, net of applicable taxes and without interest, and (ii) one non-transferable contractual contingent value right."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-047836","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919123047836/doc4.xml","form_type":"4"}},{"id":1858530,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-12T20:50:44.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":2.88,"expiration_date":"2033-06-08","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001610717-23-000144","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000161071723000144/form4.xml","form_type":"4"}},{"id":2032552,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-03T21:36:31.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":562500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Option vests over four years with 1/48th of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 1st day of each month after the Grant Date (02/01/2023), subject to continued service relationship."}],"balance_after":562500,"derivative":{"exercise_price":2.08,"expiration_date":"2033-02-01","underlying":"Common Stock","underlying_shares":562500},"source":{"system":"sec-edgar","filing":"0001209191-23-006896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919123006896/doc4.xml","form_type":"4"}},{"id":2043973,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-01-27T16:34:27.000Z","date":"2023-01-25","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2023."}],"balance_after":25000,"derivative":{"exercise_price":7.8,"expiration_date":"2033-01-24","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001062993-23-001498","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299323001498/form4.xml","form_type":"4"}},{"id":2093162,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-07T21:29:11.000Z","date":"2022-12-05","kind":"purchase","acquired":true,"shares":12500,"price":1.09,"value":13625.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in Column 4 is a weighted average price. The prices actually paid ranged from $1.02 to $1.20. The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001209191-22-060154","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919122060154/doc4.xml","form_type":"4"}},{"id":2095808,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-05T21:21:21.000Z","date":"2022-12-02","kind":"purchase","acquired":true,"shares":12500,"price":1.07,"value":13375.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $1.02 to $1.12."}],"balance_after":37500,"source":{"system":"sec-edgar","filing":"0001209191-22-059677","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919122059677/doc4.xml","form_type":"4"}},{"id":2095807,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-12-05T21:21:21.000Z","date":"2022-12-01","kind":"purchase","acquired":true,"shares":25000,"price":1.04,"value":26000.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $0.96025 to $1.05."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range."}],"balance_after":25000,"source":{"system":"sec-edgar","filing":"0001209191-22-059677","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919122059677/doc4.xml","form_type":"4"}},{"id":2136934,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T20:06:14.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":6750,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":6.12,"underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0000899243-22-033650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322033650/doc4.xml","form_type":"4"}},{"id":2136933,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T20:06:14.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":8375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":25.35,"underlying":"Common Stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0000899243-22-033650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322033650/doc4.xml","form_type":"4"}},{"id":2136932,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-10-14T20:06:14.000Z","date":"2022-10-14","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, an amount in cash equal to the excess, if any, of the Merger Consideration over the exercise price per share of such option. Each option that was outstanding and unexercised immediately prior to the Effective Time which had a per share exercise price greater than or equal to the Merger Consideration was cancelled with no consideration payable."}],"balance_after":0,"derivative":{"exercise_price":39.5,"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-033650","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322033650/doc4.xml","form_type":"4"}},{"id":2136931,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-10-14T20:06:14.000Z","date":"2022-10-14","kind":"other","acquired":false,"shares":7250,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of August 31, 2022, by and among Forma Therapeutics Holdings, Inc. (the \"Issuer\"), Novo Nordisk A/S (the \"Parent\"), and NNUS New Dev, Inc., a wholly owned indirect subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\"), effective as of October 14, 2022 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $20.00 in cash (the \"Merger Consideration\"), subject to withholding of applicable taxes and without interest."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"shares","element":"transactionShares","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Consists of restricted stock units (\"RSUs\"), including those RSUs settled into Shares upon vesting. Pursuant to the terms of the Merger Agreement, at the Effective Time, each RSU (whether vested or unvested) that was outstanding immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such RSU, an amount in cash equal to the Merger Consideration, subject to withholding of applicable taxes and without interest."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-22-033650","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322033650/doc4.xml","form_type":"4"}},{"id":2157165,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-16T20:17:13.000Z","date":"2022-09-14","kind":"grant","acquired":true,"shares":450000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/2 of the shares subject to such option vest and become exercisable on September 14, 2023, and 1/24th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on the 14th day of each month thereafter, subject to continued service relationship.\nOptions vest over two years with 1/2 of the shares subject to such option vesting and becoming exercisable on September 14, 2023, and the remaining 1/2 of the shares subject to such option vesting and becoming exercisable in substantially equal monthly installments on the 14th day of each month thereafter, subject to continued service relationship."}],"balance_after":450000,"derivative":{"exercise_price":2.98,"expiration_date":"2032-09-14","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0001209191-22-050318","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000120919122050318/doc4.xml","form_type":"4"}},{"id":2233875,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-13T20:44:15.000Z","date":"2022-06-09","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":24000,"derivative":{"exercise_price":3.84,"expiration_date":"2032-06-09","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001567619-22-012781","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156761922012781/doc1.xml","form_type":"4"}},{"id":2237488,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-09T21:34:49.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":6750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 8, 2023 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":6750,"derivative":{"exercise_price":6.12,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":6750},"source":{"system":"sec-edgar","filing":"0000899243-22-021666","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322021666/doc4.xml","form_type":"4"}},{"id":2237487,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-06-09T21:34:49.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":7250,"source":{"system":"sec-edgar","filing":"0000899243-22-021666","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322021666/doc4.xml","form_type":"4"}},{"id":2349946,"issuer":{"id":110063,"kind":"organization","name":"PARDES BIOSCIENCES, INC.","symbol":"PRDS"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T21:40:26.000Z","date":"2022-03-02","kind":"grant","acquired":true,"shares":985000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4th of the shares subject to such option vest and become exercisable on the first anniversary of March 1, 2022 and the remaining 3/4th of the shares subject to such option will vest and become exercisable in substantially equal monthly installments on the 1st day of each month thereafter, subject to a continued service relationship."}],"balance_after":985000,"derivative":{"exercise_price":6.36,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":985000},"source":{"system":"sec-edgar","filing":"0000899243-22-009403","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924322009403/doc4.xml","form_type":"4"}},{"id":2424287,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-27T16:54:27.000Z","date":"2022-01-25","kind":"grant","acquired":true,"shares":67000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/12 of the underlying shares monthly from January 1, 2022."}],"balance_after":67000,"derivative":{"exercise_price":2.94,"expiration_date":"2032-01-24","underlying":"Common Stock","underlying_shares":67000},"source":{"system":"sec-edgar","filing":"0001062993-22-001696","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000106299322001696/form4.xml","form_type":"4"}},{"id":2660527,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-21T23:05:50.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":8375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 17, 2022 and (ii) the next annual meeting of the Issuer's stockholders."}],"balance_after":8375,"derivative":{"exercise_price":25.35,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":8375},"source":{"system":"sec-edgar","filing":"0000899243-21-025095","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924321025095/doc4.xml","form_type":"4"}},{"id":2660526,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-21T23:05:50.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares represented restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock."}],"balance_after":2750,"source":{"system":"sec-edgar","filing":"0000899243-21-025095","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924321025095/doc4.xml","form_type":"4"}},{"id":2680671,"issuer":{"id":5011,"kind":"organization","name":"Annexon, Inc.","symbol":"ANNX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T21:12:11.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 2, 2021 or (ii) the next Annual Meeting following June 2, 2021, subject to Reporting Person's continuous service as a director until such vesting date."}],"balance_after":10000,"derivative":{"exercise_price":21.03,"expiration_date":"2031-06-02","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001567619-21-011722","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156761921011722/doc1.xml","form_type":"4"}},{"id":2758625,"issuer":{"id":92768,"kind":"organization","name":"CymaBay Therapeutics, Inc.","symbol":"CBAY"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-05T17:01:11.000Z","date":"2021-04-05","kind":"grant","acquired":true,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 1/36 of the underlying shares monthly from April 5, 2021."}],"balance_after":80000,"derivative":{"exercise_price":4.63,"expiration_date":"2031-04-04","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001333277-21-000036","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1042074/000133327721000036/edgar.xml","form_type":"4"}},{"id":3035232,"issuer":{"id":123059,"kind":"organization","name":"Forma Therapeutics Holdings, Inc.","symbol":"FMTX"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-09-09T20:05:09.000Z","date":"2020-09-07","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33.3% of the shares subject to the stock option shall vest on September 7, 2021; and the remainder of the shares shall vest in equal monthly installments for a period of 24 months thereafter, subject to continued service with the Issuer."}],"balance_after":0,"derivative":{"exercise_price":39.5,"expiration_date":"2030-09-06","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-20-024633","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000089924320024633/doc4.xml","form_type":"4"}},{"id":3252552,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252551,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252550,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":9000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira restricted stock unit (\"RSU\"), whether vested or unvested, was canceled and converted into the right to receive an amount of cash equal to the product of (x) the number of Shares underlying such Dermira RSU multiplied by (y) the Offer Price."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252549,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":300000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":7.42,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252548,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":150000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":28.25,"expiration_date":"2028-02-14","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252547,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":33.84,"expiration_date":"2027-02-16","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252546,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":180000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":26.37,"expiration_date":"2026-02-04","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252545,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":355170,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2024-10-01","underlying":"Common Stock","underlying_shares":355170},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252544,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":98430,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.74,"expiration_date":"2023-07-10","underlying":"Common Stock","underlying_shares":98430},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252543,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":64327,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.218,"expiration_date":"2023-01-03","underlying":"Common Stock","underlying_shares":64327},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252542,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":115022,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":1.218,"expiration_date":"2023-01-03","underlying":"Common Stock","underlying_shares":115022},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252541,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":164642,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, immediately prior to the Effective Time, each Dermira stock option, whether vested or unvested, was canceled and converted into the right to receive an amount in cash equal to the product of (x) the number of Shares issuable under such option multiplied by (y) the excess, if any, of (A) the Offer Price over (B) the per share exercise price of such option.  Any outstanding Dermira stock options with an exercise price equal to or greater than the Offer Price were canceled for no consideration at the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":164642},"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252540,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":180985,"price":18.75,"value":3393468.75,"ownership":{"direct":false,"nature":"By the Wiggans Living Trust dated 5/14/02"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The Reporting Person is a Co-Trustee."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252539,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-20","kind":"disposition_to_issuer","acquired":false,"shares":49963,"price":18.75,"value":936806.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\") dated January 10, 2020, by and among Dermira, Inc. (\"Dermira\"), Eli Lilly and Company, an Indiana corporation (\"Lilly\"), and Bald Eagle Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of Lilly (\"Merger Sub\"), Merger Sub merged with and into Dermira, with Dermira surviving as a wholly owned subsidiary of Lilly (the \"Merger\"), effective as of February 20, 2020.  Pursuant to the Merger Agreement, each issued and outstanding share (the \"Shares\") of Dermira common stock, par value $0.001 per share, was purchased at a price of $18.75 per share (the \"Offer Price\"), net to the seller in cash, without interest, and subject to withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3252538,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2020-02-25T00:31:54.000Z","date":"2020-02-05","kind":"gift","acquired":false,"shares":27000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 1,023 shares of Dermira Common Stock acquired by the Reporting Person pursuant to Dermira's Employee Stock Purchase Plan."}],"balance_after":49963,"source":{"system":"sec-edgar","filing":"0001562180-20-001616","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218020001616/primarydocument.xml","form_type":"4"}},{"id":3434237,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Fully vested August 15, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Fully vested August 15, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434236,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"exercise","acquired":false,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Vested as to 10% of the shares on August 15, 2018 and 30% of the shares on August 15, 2019. 30% of the shares will vest on each of August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Vested as to 10% of the shares on August 15, 2018 and 30% of the shares on August 15, 2019. 30% of the shares will vest on each of August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434235,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on each of August 15, 2018 and August 15, 2019. The remaining 30% of the shares will vest on August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on each of August 15, 2018 and August 15, 2019. The remaining 30% of the shares will vest on August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434234,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-19","kind":"purchase","acquired":true,"shares":23419,"price":8.54,"value":199998.26,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"Shares purchased from Luis Pena in a private sale transaction."}],"balance_after":75940,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434233,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"tax_withholding","acquired":false,"shares":3719,"price":7.91,"value":29417.29,"ownership":{"direct":true},"balance_after":52521,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434232,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"tax_withholding","acquired":false,"shares":4463,"price":7.91,"value":35302.33,"ownership":{"direct":true},"balance_after":56240,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434231,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"tax_withholding","acquired":false,"shares":4463,"price":7.91,"value":35302.33,"ownership":{"direct":true},"balance_after":60703,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434230,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"exercise","acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":65166,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434229,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"exercise","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":57666,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434228,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-08-15","kind":"exercise","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"These shares include prior ESPP purchases."}],"balance_after":48666,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3434227,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2019-08-20T01:48:33.000Z","date":"2019-06-19","kind":"gift","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock donated as a gift to Kansas University Endowment Association."}],"balance_after":39666,"source":{"system":"sec-edgar","filing":"0001562180-19-004389","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019004389/primarydocument.xml","form_type":"4"}},{"id":3656174,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2019-02-15T00:57:43.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Vests as to 50% of the shares on March 5, 2020, 50% on March 5, 2021, subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":50000,"derivative":{"underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001562180-19-000997","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019000997/primarydocument.xml","form_type":"4"}},{"id":3656173,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2019-02-15T00:57:43.000Z","date":"2019-02-12","kind":"grant","acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on February 1, 2019, subject to the continuing employment of the Reporting person on the applicable vesting date."}],"balance_after":300000,"derivative":{"exercise_price":7.42,"expiration_date":"2029-02-11","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001562180-19-000997","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218019000997/primarydocument.xml","form_type":"4"}},{"id":3839667,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Vested as to 10% of the shares on August 15, 2016 and 30% of the shares on each of August 15, 2017 and August 15, 2018.  The remaining 30% of the shares will vest on August 15, 2019, subject to the Reporting Person's continuous status as a service provider on the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Vested as to 10% of the shares on August 15, 2016 and 30% of the shares on each of August 15, 2017 and August 15, 2018.  The remaining 30% of the shares will vest on August 15, 2019, subject to the Reporting Person's continuous status as a service provider on the vesting date."}],"balance_after":18000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839666,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"exercise","acquired":false,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on August 15, 2018.  30% of the shares will vest on each of August 15, 2019 and August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Vested as to 10% of the shares on August 15, 2017 and 30% of the shares on August 15, 2018.  30% of the shares will vest on each of August 15, 2019 and August 15, 2020, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."}],"balance_after":9000,"derivative":{"underlying":"Common Stock","underlying_shares":9000},"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839665,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Vested as to 10% of the shares on August 15, 2018. 30% of the shares will vest on each of August 15, 2019, August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Vested as to 10% of the shares on August 15, 2018. 30% of the shares will vest on each of August 15, 2019, August 15, 2020 and August 15, 2021, subject to the Reporting Person's continuous status as a service provider on the applicable vesting date."}],"balance_after":22500,"derivative":{"underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839664,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"tax_withholding","acquired":false,"shares":3113,"price":9.58,"value":29822.54,"ownership":{"direct":true},"balance_after":92919,"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839663,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"tax_withholding","acquired":false,"shares":3113,"price":9.58,"value":29822.54,"ownership":{"direct":true},"balance_after":96032,"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839662,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"tax_withholding","acquired":false,"shares":865,"price":9.58,"value":8286.7,"ownership":{"direct":true},"balance_after":99145,"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839661,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"exercise","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":100010,"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839660,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"exercise","acquired":true,"shares":9000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":91010,"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3839659,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-08-17T20:05:41.000Z","date":"2018-08-15","kind":"exercise","acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include prior ESPP purchases."}],"balance_after":82010,"source":{"system":"sec-edgar","filing":"0001562180-18-003674","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003674/primarydocument.xml","form_type":"4"}},{"id":3871034,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-07-09T22:57:41.000Z","date":"2018-07-09","kind":"purchase","acquired":true,"shares":12000,"price":9.9959,"value":119950.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade was made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.71 to $10.22. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These shares include prior ESPP purchases."}],"balance_after":79510,"source":{"system":"sec-edgar","filing":"0001562180-18-003257","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003257/primarydocument.xml","form_type":"4"}},{"id":3878497,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-07-02T21:04:38.000Z","date":"2018-07-02","kind":"purchase","acquired":true,"shares":13780,"price":8.7081,"value":119997.618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade was made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $8.43 to $9.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These shares include prior ESPP purchases."}],"balance_after":67510,"source":{"system":"sec-edgar","filing":"0001562180-18-003163","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003163/primarydocument.xml","form_type":"4"}},{"id":3883913,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-06-25T21:40:14.000Z","date":"2018-06-25","kind":"purchase","acquired":true,"shares":12150,"price":9.8425,"value":119586.375,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade was made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.61 to $10.21. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These shares include prior ESPP purchases."}],"balance_after":53730,"source":{"system":"sec-edgar","filing":"0001562180-18-003095","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003095/primarydocument.xml","form_type":"4"}},{"id":3890462,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-06-18T20:19:30.000Z","date":"2018-06-18","kind":"purchase","acquired":true,"shares":11875,"price":10.1014,"value":119954.125,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This trade was made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $9.885 to $10.265. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These shares include prior ESPP purchases."}],"balance_after":41580,"source":{"system":"sec-edgar","filing":"0001562180-18-003041","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018003041/primarydocument.xml","form_type":"4"}},{"id":3930496,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2018-05-16T22:43:02.000Z","date":"2018-05-15","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option fully vested on 10/04/2015."}],"balance_after":164642,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-18-002528","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018002528/primarydocument.xml","form_type":"4"}},{"id":3930495,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2018-05-16T22:43:02.000Z","date":"2018-05-15","kind":"exercise","acquired":true,"shares":10000,"price":0.986,"value":9860.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"These shares include prior ESPP purchases."}],"balance_after":29705,"source":{"system":"sec-edgar","filing":"0001562180-18-002528","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018002528/primarydocument.xml","form_type":"4"}},{"id":4051470,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Restricted Stock Unit","published_at":"2018-02-16T22:37:35.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each RSU represents a contingent right to receive one share of DERM common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Vests as to 10% of the shares on August 15, 2018, 30% on August 15, 2019, 30% on August 15, 2020, 30% on August 15,2021, subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each RSU represents a contingent right to receive one share of DERM common stock."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001562180-18-001049","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018001049/primarydocument.xml","form_type":"4"}},{"id":4051469,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Employee Stock Options (Right to buy)","published_at":"2018-02-16T22:37:35.000Z","date":"2018-02-15","kind":"grant","acquired":true,"shares":150000,"price":28.25,"value":4237500.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests and becomes exercisable as to 1/48th of the shares in equal monthly installments with the first 1/48th of the shares vesting on January 1, 2018, subject to the continuing employment of the Reporting person on the applicable vesting date."}],"balance_after":150000,"derivative":{"exercise_price":28.25,"expiration_date":"2028-02-15","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001562180-18-001049","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218018001049/primarydocument.xml","form_type":"4"}},{"id":4122302,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2017-12-22T21:16:40.000Z","date":"2017-12-21","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option fully vested on 1/4/2017."}],"balance_after":115022,"derivative":{"exercise_price":1.218,"expiration_date":"2023-01-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-004016","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017004016/primarydocument.xml","form_type":"4"}},{"id":4122301,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-12-22T21:16:40.000Z","date":"2017-12-21","kind":"exercise","acquired":true,"shares":5000,"price":1.218,"value":6090.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This share amount includes ESPP shares."}],"balance_after":18662,"source":{"system":"sec-edgar","filing":"0001562180-17-004016","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017004016/primarydocument.xml","form_type":"4"}},{"id":4130108,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2017-12-15T21:36:31.000Z","date":"2017-12-13","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option fully vested on 10/04/2015."}],"balance_after":174642,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-003892","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003892/primarydocument.xml","form_type":"4"}},{"id":4130107,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-12-15T21:36:31.000Z","date":"2017-12-13","kind":"sale","acquired":false,"shares":5000,"price":27.5131,"value":137565.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13662,"source":{"system":"sec-edgar","filing":"0001562180-17-003892","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003892/primarydocument.xml","form_type":"4"}},{"id":4130106,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-12-15T21:36:31.000Z","date":"2017-12-13","kind":"exercise","acquired":true,"shares":5000,"price":0.986,"value":4930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This share amount includes ESPP shares."}],"balance_after":18662,"source":{"system":"sec-edgar","filing":"0001562180-17-003892","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003892/primarydocument.xml","form_type":"4"}},{"id":4172518,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2017-11-03T21:19:43.000Z","date":"2017-11-02","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option fully vested on 10/04/2015."}],"balance_after":179642,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-003469","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003469/primarydocument.xml","form_type":"4"}},{"id":4172517,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-11-03T21:19:43.000Z","date":"2017-11-02","kind":"sale","acquired":false,"shares":5000,"price":27.5216,"value":137608.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.625. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13427,"source":{"system":"sec-edgar","filing":"0001562180-17-003469","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003469/primarydocument.xml","form_type":"4"}},{"id":4172516,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-11-03T21:19:43.000Z","date":"2017-11-02","kind":"exercise","acquired":true,"shares":5000,"price":0.986,"value":4930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This share amount includes ESPP shares."}],"balance_after":18427,"source":{"system":"sec-edgar","filing":"0001562180-17-003469","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003469/primarydocument.xml","form_type":"4"}},{"id":4187905,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Stock Options (Right to buy)","published_at":"2017-10-11T23:39:55.000Z","date":"2017-10-10","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option fully vested on 10/04/2015."}],"balance_after":184642,"derivative":{"exercise_price":0.986,"expiration_date":"2021-10-03","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-17-003247","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003247/primarydocument.xml","form_type":"4"}},{"id":4187904,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-10-11T23:39:55.000Z","date":"2017-10-10","kind":"sale","acquired":false,"shares":5000,"price":27.5212,"value":137606.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $27.50 to $27.57. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":13427,"source":{"system":"sec-edgar","filing":"0001562180-17-003247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003247/primarydocument.xml","form_type":"4"}},{"id":4187903,"issuer":{"id":11896,"kind":"organization","name":"Dermira, Inc.","symbol":"DERM"},"owners":[{"id":26600,"kind":"person","name":"WIGGANS THOMAS G","position":1,"cik":"0001208907","reported_name":"WIGGANS THOMAS G","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & Chairman of the Board"}}],"security":"Common Stock","published_at":"2017-10-11T23:39:55.000Z","date":"2017-10-10","kind":"exercise","acquired":true,"shares":5000,"price":0.986,"value":4930.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These trades were made pursuant to a Rule 10b5-1 trading plan."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This share amount includes ESPP shares."}],"balance_after":18427,"source":{"system":"sec-edgar","filing":"0001562180-17-003247","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1208907/000156218017003247/primarydocument.xml","form_type":"4"}}],"next_cursor":"2017-10-11T23:39:55.000000Z,4187903"}